Biotech startup Zumutor Biologics has raised $7.3 million in its pre-Series B financing round. In another development, industrial AI transformation platform AutoVRse has secured $2.4 million in fresh funding.
Zumutor Biologics raises $7.3m
Biotech startup Zumutor Biologics has raised $7.3 million in its pre-Series B funding round from existing investors Accel and Bharat Innovation Fund. The financing also saw participation of new investors Premji Invest, Ashish Kacholia, and Raj Dandu Family Office.
The proceeds will be used to complete the ongoing US FDA Phase 1 clinical trial of its lead drug candidate ZM008, support Phase 1B expansion cohorts, and initiate global Phase 2 studies, including in India.
Founded by Kavitha Iyer Rodrigues, Zumutor Biologics is a biotechnology company focused on developing next-generation immuno-oncology therapies that harness the body’s immune system, particularly natural killer (NK) cells, to fight cancer. ZM008, which it describes as a first-in-class NK cell checkpoint therapy, entered human trials in 2024.
Singularity AMC backs AutoVRse
AutoVRse, an industrial AI transformation platform, on Monday (June 15) announced that it has raised $2.4 million in a funding round, co-led by Singularity AMC’s Large Value Fund III and Early Opportunities Fund, and existing investor Lumikai.
The capital will be deployed to accelerate product development across critical industries, deepen integrations with customer infrastructure, and scale go-to-market efforts across North America, where AutoVRse is already running deployments, it said in a statement. The company also plans to expand further in Europe, the GCC and India.
AutoVRse deploys VR-based training and smart glasses-enabled field guidance across manufacturing, pharmaceuticals, energy and healthcare. The company claims to serve 500,000+ users at more than 50 enterprise customers across North America, Europe, the GCC and India, including Amazon, Shell, ADNOC, Exxon Mobil, Bosch, NTPC, HDFC Bank, UltraTech Cement, JSW Steel, Tata Power, Vedanta, Hindalco, and Godrej.
